New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
08:25 EDTBCRX, BCRXBioCryst to host conference call
Conference call to discuss results from the BCX4161 OPuS-1 phase 2 trial for hereditary Angioedema on May 27 at 8:30 am. Webcast Link
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
09:20 EDTBCRXOn The Fly: Pre-market Movers
Subscribe for More Information
06:27 EDTBCRXBioCryst volatility flat into CDC confirms first U.S. Ebola case in Texas
Subscribe for More Information
September 30, 2014
18:36 EDTBCRXOn The Fly: After Hours Movers
Subscribe for More Information
17:58 EDTBCRXCDC confirms first U.S. patient diagnosed with Ebola virus
Subscribe for More Information
17:39 EDTBCRXCompanies developing Ebola treatments rise after CDC confirms U.S. Ebola case
Subscribe for More Information
16:47 EDTBCRXBioCryst up 5% after hours following CDC confirmation of Ebola case in U.S.
Subscribe for More Information
September 26, 2014
07:47 EDTBCRXEMA to review BioCryst, Sarepta, Tekmira experimental Ebola medicines
Subscribe for More Information
September 18, 2014
12:08 EDTBCRXBioCryst receives additional NIAID funding for BCX4430
BioCryst announced that the National Institute of Allergy and Infectious Diseases exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2M increase to the existing development contract. The contract modification and the two additional options exercised represent up to $4M to BioCryst in order to accelerate the development of BCX4430 as a treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. NIAID, part of the National Institutes of Health, granted this five year term contract to BioCryst in September 2013. Approximately $19.9M of funding has been awarded to date under the contract. With this additional award, the BCX4430 development contract has been increased in value to $26.3M, if all options are exercised. This project is funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use